FLT3 and acute myeloid leukemia: CEP-701 known as Lestaurtinib is an Fms-like tyrosine kinase 3 (FLT3) inhibitor in current use on acute myeloid leukemia clinical trials and a JAK2 kinase inhibitor which suppresses phosphorylation induced by JAK2 tyrosine kinase.